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Summary
Naturally transmissible tumours can emerge when a tumour cell gains the
ability to pass as an infectious allograft between individuals. The ability of
these tumours to colonize a new host and to cross histocompatibility bar-
riers contradicts our understanding of the vertebrate immune response to
allografts. Two naturally occurring contagious cancers are currently active
in the animal kingdom, canine transmissible venereal tumour (CTVT),
which spreads among dogs, and devil facial tumour disease (DFTD),
among Tasmanian devils. CTVT are generally not fatal as a tumour-spe-
cific host immune response controls or clears the tumours after transmis-
sion and a period of growth. In contrast, the growth of DFTD tumours is
not controlled by the Tasmanian devil’s immune system and the disease
causes close to 100% mortality, severely impacting the devil population.
To avoid the immune response of the host both DFTD and CTVT use a
variety of immune escape strategies that have similarities to many single
organism tumours, including MHC loss and the expression of immuno-
suppressive cytokines. However, both tumours appear to have a complex
interaction with the immune system of their respective host, which has
evolved over the relatively long life of these tumours. The Tasmanian
devil is struggling to survive with the burden of this disease and it is only
with an understanding of how DFTD passes between individuals that a
vaccine might be developed. Further, an understanding of how these
tumours achieve natural transmissibility should provide insights into gen-
eral mechanisms of immune escape that emerge during tumour evolution.
Keywords: cancer; comparative immunology/evolution; MHC; transplan-
tation; tumour immunology
Introduction
The ability of the immune system to prevent cancer was
initially proposed by Paul Ehrlich in 19021 and expanded
by Burnett in his hypothesis of cancer immunosurveil-
lance.2 Since then our understanding of how the immune
system targets tumour cells has improved greatly, but it
has also become apparent that tumour cells employ a
variety of strategies to successfully avoid and suppress the
immune response.3,4 Given the ability of tumour cells to
manipulate the immune system, it is perhaps not surpris-
ing that tumour cells can acquire the ability to pass
between individuals without experimental inoculation,
developing into a contagious cancer. However, naturally
occurring contagious cancers arise very rarely, in part due
to the efficiency with which the vertebrate immune
system distinguishes foreign from self cells, a process
well-characterized during allograft rejection. Indeed, the
mechanisms of allograft rejection were explored, in part,
using transplantable tumours in murine models. These
studies revealed elements of how grafts are rejected and
how tumours can escape the immune system.5
To our knowledge only two contagious cancers have
emerged naturally: canine transmissible venereal tumour
(CTVT), which passes between dogs, and devil facial
tumour disease (DFTD), which passes between Tasma-
nian devils. Despite the shared ability of these tumour
cells to pass between individuals they have a very differ-
ent impact on their respective hosts. While CTVT is not
lethal to dogs and has existed for approximately
10 000 years,6 DFTD causes close to 100% mortality
among infected devils and has had a devastating impact
on this species over less than two decades.7,8
As allografts, contagious cancer cells should be easily
rejected because of the histocompatibility barriers between
individuals. Rapid immune response to allografts occurs
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when host CD4 and CD8 T cells are exposed to foreign
Major Histocompatibility Complex (MHC) molecules on
the surface of donor cells,9 most commonly donor antigen-
presenting cells (APCs) that are present in a graft. These
APCs move to the draining lymph nodes of the host, after
which primed effector T cells migrate back to the graft site
and target foreign cells (reviewed in ref. 10). Alternatively,
T cells can be primed with graft-derived peptides (generally
minor histocompatibility antigens) that are taken up by
the host APCs and presented to host T cells by MHC mole-
cules, causing slower rejection of the graft.11 B cells also
contribute to anti-graft responses by generating alloanti-
bodies that directly recognize donor antigens and trigger
rapid rejection.12
Although tumours can represent a more difficult target
for the immune system, malignant cells can be targeted by
T cells and natural killer (NK) cells, helped by the release of
the pro-inflammatory cytokine interferon-c (IFN-c).3,13
Malignant cells can produce self-antigens mutated by
malignancy, and although responses to these antigens are
not likely to be as rapid or robust as in allografts they have
formed the basis for immunotherapy for some human
tumours.3,14 In addition, malignancy can lead to the
expression of activation ligands that can engage NK cells.15
However, haematopoietic and solid tumours can also gen-
erate immunological tolerance through a range of mecha-
nisms, including the expression of inhibitory ligands
(notably programmed death ligand 1), the release of immu-
nosuppressive cytokines [i.e. transforming growth factor-b
(TGF-b) and interleukin-10 (IL-10)], loss of MHC mole-
cules and the generation of a microenvironment around
the tumour that facilitates growth and immune suppres-
sion (reviewed in ref. 16). In addition, tumours often rep-
resent a ‘moving target’ for the immune system, acquiring
mutations that facilitate immune escape in a process
described as immunoediting (reviewed in ref. 17).
There are many reviews detailing the ways in which
tumours are targeted by the immune system and mecha-
nisms of immune escape (see ref. 14–17 as examples).
This review will focus on the immune response to conta-
gious cancers, the ways in which contagious cancers
escape the robust allograft immune response of the host
and what we can learn about the emergence of these
tumours.
Canine transmissible venereal tumour
Interest in CTVT as an infectious cancer dates from the
1870s when Novinsky showed that CTVT cells could be
transferred between dogs.18 Tumour cells are naturally
passed between individuals during coitus, with tumours
developing around the genitalia and less commonly
around the nose and mouth via sniffing and licking
behaviours.19,20 CTVT cells can also be transmitted exper-
imentally by subcutaneous injection at a variety of
sites21,22 and tumour cells will grow in foxes, wolves and
coyotes (reviewed in ref. 23).
CTVT does not readily metastasize or kill host dogs
except where the host is a puppy or is immunocompro-
mised.24 Instead, following transmission, tumour cells
undergo a period of growth followed by stasis and/or
regression. Under experimental conditions, approximately
13% of CTVT cells are reported to survive transmission
and form a visible tumour,21 with little cell death for
between 1 and 3 months.24–27 This is followed by either a
period of stasis, where the tumour mass does not increase
or decrease; immediate regression of the tumour; or stasis
followed by regression.22,28 The length of these phases
varies (particularly outside the laboratory setting); in
some cases no stationary phase is evident (rather the
tumour grows and then regresses) and in others the
tumour remains in stasis without full regression.28 This
variation may depend on whether the tumour was inocu-
lated or naturally spread,29 the immune status of the
host24,25 and the genetic background of the host dog,
including the MHC genotype.26 CTVT cells are suscepti-
ble to radiotherapy and chemotherapy, with vincristine
being the preferred treatment.29 However, CTVT remains
prevalent in temperate climates and where stray and feral
dogs are common, providing a reservoir of disease.30
First visible as firm nodules, during growth CTVTs
become multilobed and up to 10 cm in diameter22
(Fig. 1). Once tumours are established they are described
as clusters of closely packed cells that are arranged along
fibrous connective tissue and blood vessels.23 The original
transformed cell remains obscure but a histiocytic origin
has been suggested as the cells are positive for lysozyme
and vimentin.31,32 CTVT cells can become infected with
leishmania parasites,33 and a recent study of the tran-
scriptome of CTVT cells demonstrated expression of
genes associated with antigen presentation during the
regressing stage of the tumour.34
CTVT is the oldest known cancer, existing for an esti-
mated 10 000 years.6 From a single neoplastic clone,
CTVT has evolved into numerous sub-clones with differ-
ent geographic locations hosting particular sub-clones.35
The evolutionary history of the tumour indicates that
local expansions followed the spread of a clone to a new
continent.35 Rebbeck et al. predict that the most recent
common ancestor of extant tumours existed as much as
470 years ago, but that the tumour may have emerged up
to 78 000 years ago in a wolf or an old breed of dog,36
whereas the most recent estimate predicts emergence
between 10 000 and 12 000 years ago.6
Devil facial tumour disease
The Tasmanian devil is a marsupial carnivore endemic
to the island of Tasmania. The species suffered popula-
tion reductions with the arrival of European settlers to
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Tasmania, but over time the population recovered, with
an estimated 130 000–150 000 devils in Tasmania in the
early 1990s.8 Between 1996 and 2001 devils were identi-
fied across the east coast of Tasmania with large disfigur-
ing tumours (termed DFTD) around their faces and
necks, and local declines in devils were reported.37
DFTD tumours are first visible as nodules < 1 cm in
diameter, but within 6 months can become greater than
10 cm in diameter, multilobed, infected and ulcerated,
sometimes with a necrotic core38 (Fig. 1). The tumours
arise in the dermis or the submucosal tissue in the oral cav-
ity, with evidence to suggest that tumours in the oral cavity
are more common.38,39 Tumour growth can affect denti-
tion and in some cases the jaw becomes dislocated, affect-
ing the ability to feed, while in approximately 65% of cases
the tumour will metastasize and animals may die from
associated organ failure.38 The latency period in the wild
has been difficult to determine, but is likely to vary from 2
to 13 months (M. Jones and R. Hamede, pers. comm.),
while tumour development after experimental inoculation
appears to be less variable with a pea-size tumour visi-
ble within 5–22 weeks (using 25 9 104 tumour cells) (A.
Kreiss, pers. comm.). Devils typically succumb to the dis-
ease between 3 and 9 months after tumours are visible, but
in rare cases animals can survive for up to 12 months
(M. Jones and R. Hamede, pers. comm.). Early studies on
DFTD concluded that the tumour has a neuroendocrine
origin40 and subsequent sequencing of mRNA transcripts
and microRNAs further defined the cells as originating
from a Schwann cell,41 positive for markers associated with
Schwann cell differentiation, such as periaxin, S-100 and
myelin basic protein.41,42
In 2006 Pearse and Swift proposed that DFTD was
passing as an allograft based on the observation that
DFTD cells from different individuals across Tasmania
have near-identical chromosomal rearrangements.43 Sub-
sequent genetic analyses confirmed the common origin of
DFTD tumours.41,44 Fine mapping of the chromosomal
rearrangements in DFTD cells has shown extensive frag-
mentation of chromosomes 1 and X, regions that are also
extensively rearranged between the tammar wallaby, Tas-
manian devil and American opossum karyotypes, perhaps
indicating underlying fragility in these regions.45 Like
CTVT, there is evidence that DFTD is evolving into dis-
tinct sub-clones,43,46,47 based on variation in karyotype47
and single nucleotide polymorphisms.46
Although they do not live in social groups, Tasmanian
devils interact when they feed at carcasses and during the
(a)
(i)
(ii)
(iii)
(i)
(ii)
(b)
Figure 1. Pathology of canine transmissible
venereal tumour (CTVT) and devil facial
tumour disease (DFTD. (a) External view of
CTVT and DFTD tumours (i) a CTVT tumour
at the base of the penis, (ii) a DFTD tumour
on the inner lip before ulceration and, (iii) an
advanced DFTD tumour that is ulcerated and
disrupting dentition. CTVT image is courtesy
of Dr Elizabeth Murchison and Andrea Strak-
ova. (b) Haematoxylin & eosin stained biopsies
at 409 magnification (i) CTVT and (ii) DFTD,
scale bars 50 lm. CTVT image is courtesy of
Andrea Strakova.
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mating season.48 These interactions commonly involve
biting to establish dominance and hierarchy, and can be
male–male, female–female and male–female.49,50 As the
overwhelming majority of DFTD tumours are found
around the face and neck of affected animals, it is
thought that tumour cells are passed by biting, even
though infection via fomites such as hair and skin cannot
be excluded.49,51 There is no bias in transmission between
males and females nor any evidence for vertical transmis-
sion between mothers and joeys, but sexual maturity
appears to be important for transmission, with only
adults contracting the disease, fitting with an increase in
biting behaviour with the onset of mating.49
DFTD has had a destructive impact on the Tasmanian
devil population, with close to 100% mortality.8 After
DFTD enters a population there is a rapid decline in devil
numbers37,52 and also increased inbreeding in some popu-
lations.53 Further, as transmission is not density dependent,
the frequency of disease is maintained even as devil density
falls.8 Hamede et al.54 observed an exception to this pattern
in West Pencil Pine where the prevalence of the disease
remained at around 10% for 5 years. However, 5 years
after disease arrival the prevalence increased to 50% and
the population declined.54 The reasons for this remain
unclear, but may include changes in the sub-clone present,
genetics of the host or changes in host behaviour.54
The immune response to CTVT and DFTD
While CTVT is not usually lethal to host dogs, DFTD
causes close to 100% mortality (Table 1). Dogs can raise
a protective immune response against CTVT and the
interaction between CTVT and the dog immune system is
reasonably well characterized. However, no protective
immune response against DFTD has been observed and
very little is understood about how DFTD interacts with
the devil immune system.
Spontaneous regression of CTVT is observed in labora-
tory models of the disease and the immune response is
tumour specific.28,55 The transition of CTVT from growth
to regression is characterized by infiltration of CD8+ T
cells (and other immune cells) into the tumour, as would
be expected for an anti-graft response.56–58 Even when
CTVT is actively growing there is tumour infiltration by
T cells (positive for CD3), B cells (positive for CD79b+),
macrophages (L1 positive) and B cells (defined as positive
for IgG).56 NK cells have not been specifically defined in
biopsies, but may also have been captured by staining for
IgG in studies focused on B cells. As the tumour regresses
the number of immune cells (particularly CD8+ T cells)
increases, peaking when the tumour is in an early regres-
sion phase.56–58 NK cells and cytotoxic T cells from dogs
vaccinated with CTVT cells will kill CTVT cells from sta-
tionary and regressing tumours in vitro, indicating that
these cells contribute to tumour regression.59
It is still somewhat unclear what triggers the influx of
immune cells associated with the switch from growth to
regression of CTVT. However, the expression of MHC
molecules on CTVT cells is important, with CTVT cells
switching from an MHC-negative phenotype during
tumour growth to MHC-positive during tumour regres-
sion (see below for further discussion).56,60,61 Cytokines
are also thought to play a role.62 Higher concentrations
of the pro-inflammatory cytokines IL-6 and IFN-c are
detected in ex vivo cultures of tumour-infiltrating lym-
phocytes from regressing tumours compared with grow-
ing tumours and the presence of these cytokines increases
cytotoxicity of NK cells to CTVT cells in vitro62 (Fig. 2).
Once a CTVT is regressing or has entered a stationary
phase, the host dog is immune to re-inoculation, and this
immunity can be transferred via sera to naive dogs.63,64
The sera of these dogs contain IgG that will coat tumour
cells and can mediate rapid killing via antibody-depen-
dent cell-mediated cytotoxity.55,65 The antigens on CTVT
cells that trigger this response have not been characterized
in detail, but they are likely to include both MHC and
non-MHC encoded molecules.66
In contrast to CTVT, there is no protective immune
response to DFTD cells by host Tasmanian devils, and
DFTD cells are chemotherapy67 and irradiation resistant
(G. Woods, pers. comm.). There appears to be little rec-
ognition of DFTD cells by the host immune system as
very few tumours have been observed with lymphocytes
infiltrating the tumour.38 Where CD3+ cells are present in
the tumour these are CD8+ cells, rather than CD4+, per-
haps indicating that T regulatory cells are not present in
the microenvironment. MHC class II positive cells are
present in the tumours but have not been defined
Table 1. Comparison of features of devil facial tumour disease
(DFTD) and canine transmissible venereal tumour (CTVT)
DFTD CTVT
~ 16 years old ~ 10 000 years old
Passed by biting Passed during coitus
Close to 100% mortality Not fatal (Progression, Stationary and
Regression phases)
No significant infiltration
of lymphocytes
Significant infiltration of lymphocytes
during regression
Schwann cell origin Haematopoietic origin (perhaps a
macrophage cell)
MHC class I and class II
negative
MHC class I and class II negative
during progression
Epigenetic regulation of
MHC genes
Epigenetic regulation of MHC genes
Sensitive to interferon-c Sensitive to interferon-c
Unknown role of
immunosuppressive
cytokines
Cytokine regulation of immune
response by transforming growth
factor-b and interleukin-6
Low genetic diversity
of host
Host is outbred
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further.68 No reports of DFTD-specific antibodies gener-
ated in response to infection have been published. Despite
the lack of immune response to DFTD there is no evi-
dence that the cellular or humoral arms of the devil
immune system are deficient.69,70 DFTD cannot be xeno-
grafted into immunocompetent mice71 and there is no
evidence that DFTD can pass to other marsupial species
native to Tasmania (i.e. quolls), although this has not
been tested experimentally.
Immune escape by contagious cancers
Both DFTD and CTVT pass across histocompatibility
barriers to infect new individuals and to do this must
successfully evade the immune system. Below we discuss
some of the immune evasion mechanisms that have
been defined in CTVT and/or DFTD (summarized in
Table 1).
Loss of MHC expression
Many immunogenic tumours lose the expression of
MHC molecules during their progression,72,73 preventing
the presentation of tumour-specific antigens on MHC
molecules, which can generate a CD4+ and CD8+ T-cell
response to tumour cells.3 Fewer than 5% of CTVT cells
express MHC class I or class II molecules during the
growth stage (measured ex vivo using flow cytometry)
and this phenotype would contribute to the ability of
CTVT cells to avoid the T-cell response.62 The mecha-
nism behind MHC loss has not been studied in detail,
but CTVT cells have been reported as negative for b2-
microglobulin.74 In contrast, during tumour regression
30–40% of CTVT cells express MHC class I and/or
MHC class II molecules60–62 (Fig. 2). Ex vivo studies on
CTVT tumours indicate that it is IFN-c derived from
tumour-infiltrating lymphocytes that directly induces
(a) CTVT progression
(b) DFTD progression
B cell
T cell
T cell
IL-6 T cell
T cell
NK cell
NK cell
IFN-γ 
(i) Before IFN-γ treatment (ii) After IFN-γ treatment
IFN-γ 
IFN-γ 
IFN-γ 
TGF-β
TGF-β
TGF-β
FC receptor
KIR-like
receptor
NK cell
?
?
?
(i) Growth phase (ii) Regression phase
MHC class I MHC class II
De-acetylated
chromatin
NK cell
CTVT
 cell
CTVT
 cell
DFTD
 cell
DFTD
 cell
CTVT
 cell
Figure 2. Current model of the interaction of canine transmissible venereal tumour (CTVT) and devil facial tumour disease (DFTD) with host
immune cells. (a) CTVT progression can be characterized by growth and regression phases. During growth (i) CTVT cells lack MHC molecules
and release transforming growth factor-b (TGFb), which suppresses T cells and natural killer (NK) cells and may prevent expression of MHC.
IgG coats CTVT cells and may contribute to the ability of B cells and NK cells to recognize MHC-negative CTVT cells. During regression (ii)
interleukin-6 (IL-6) is released by infiltrating lymphocytes, perhaps antagonizing TGF-b. The concentration of interferon-c (IFN-c) increases and
MHC class I and class II molecules are expressed on 40–60% of CTVT cells, leading to cytotoxicity by T cells and NK cells. (b) DFTD progres-
sion is not characterized by different phases of growth and regression, but DFTD cells are sensitive to IFN-c. Before IFN-c treatment (i) antigen
processing and presenting genes are epigenetically down-regulated and MHC molecules are not present on DFTD cells. There are few lympho-
cytes infiltrating the tumour and the reason for NK cell ignorance is not known. After IFN-c treatment (ii) DFTD cells express MHC class I and
class II molecules but why this does not lead to a protective immune response is not known.
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MHC class I and class II expression.62 Interestingly, only
a subset of CTVT cells express MHC molecules and it
seems likely that NK cells are required to target the
remaining MHC-negative cells.
DFTD cells also lack cell surface MHC class I mole-
cules.75 In this case MHC loss is due to down-regula-
tion of b2-microglobulin and the transporters for
antigen processing (TAP) genes that are essential for
peptide presentation by MHC class I molecules. In
addition, while DFTD cells express MHC class II b-
chain mRNA, there is no expression of class II a-chain
or non-classical MHC class II (DM) transcripts.75 The
DFTD b2-microglobulin and TAP genes do not have
any structural mutations that would explain the lack of
expression. Instead, these genes are regulated, at least
in part, by histone modifications affecting the acetyla-
tion state of the relevant promoters.75
Like CTVT, DFTD cells are also susceptible to IFN-c
treatment, and recombinant devil IFN-c results in a sig-
nificant up-regulation of MHC class I protein on the sur-
face of DFTD cells in vitro. Instances of MHC class I
expression on DFTD cells have also been found in sec-
tions of tumours where CD3-positive lymphocytes are
adjacent to DFTD cells, suggesting some immunological
recognition.75
Immunosuppressive cytokines
Malignant cells can suppress the immune system and
promote an environment favouring tumour growth by
the release of cytokines and chemokines. TGF-b has an
immunosuppressive effect on T cells and NK cells and
can also suppress the ability of IFN-c to up-regulate
MHC expression by interrupting the activity of the
transcription factor MHC class II transactivator.59,62
TGF-b has been detected in CTVT supernatants deri-
ved from both progressing and regressing tumours
(Fig. 2), where it is thought to abrogate the effects
IFN-c (released by lymphocytes), providing an immu-
nosuppressive environment.62 However, the IL-6
released by infiltrating lymphocytes has been shown to
antagonize TGF-b, allowing IFN-c to stimulate MHC
expression on CTVT cells.59 IL-6 and IFN-c may also
be promoting a more general inflammatory response
that contributes to tumour regression. As discussed
above, the mechanisms behind the ‘switch’ between
CTVT growth and regression are still to be fully deter-
mined.
Only one study has investigated the expression of
immunosuppressive cytokines by DFTD cells. It was
reported that TGF-b and IL-10 mRNA levels in DFTD
biopsies are not significantly higher than in spleen and
nerve tissue.76 However, only quantitative RT-PCR was
used for detection and, as these cytokines are active at
concentrations as low as 01 ng/ml, more sensitive meth-
ods of detection are needed to assess protein expression
in complex biopsy and tissue samples.
Loss of heterozygosity and genetic diversity
Loss of heterozygosity is often responsible for MHC loss
in tumours77 and may have been positively selected dur-
ing CTVT evolution, reducing the MHC mismatches
between tumour and host dogs. Although CTVT appears
to pass between dogs regardless of the host MHC geno-
type, evidence suggests that the MHC type of dogs can
affect CTVT growth patterns.26 Sib pairs with identical
MHC (in dogs, DLA) haplotypes have concordant CTVT
growth patterns, while sib pairs that differ by two DLA
haplotypes can have completely discordant growth pat-
terns. These studies were conducted before accurate
genetic typing of MHC genes was possible, and some of
these studies could be revisited with more modern tech-
niques to investigate the relationship between MHC
genotype and tumour growth. CTVT tumours are dip-
loid for the MHC class II genes DRA and DRB1, but
some tumours are haploid for DQA and DQB.35 The
diploid loci are homozygous with the exception of
DRB1 and DLA-88, which both have highly similar
alleles.
Loss of heterozygosity has not been examined in
DFTD because the complex MHC region has been dif-
ficult to assemble from available genomic resources.
However, low genetic diversity of the host has been
considered to explain the lack of immune response to
DFTD.43,44 Tasmanian devils have three known classical
MHC class I loci, SahaUA, SahaUB and SahaUC, with
classical class I alleles from these loci sharing between
91 and 99% amino acid identity.78 Interestingly, 54%
of devils carry a haplotype in which UA is a pseudo-
gene, leaving these animals with two classical class I
genes.79 Single-stranded conformation polymorphisms
analysis and sequencing of MHC class I alleles (from
SahaUA, SahaUB and SahaUC) have shown that eastern
Tasmanian devils share many alleles and 30% of ani-
mals have the same MHC genotype as DFTD (based
on single-stranded conformation polymorphisms).44,80
There is some population structuring across Tasmania
between eastern and northwestern devils80–82 and this is
reflected in stronger mixed lymphocyte reactions
observed in eastern versus western Tasmanian devils
when compared with western versus western devils and
eastern versus eastern devils.83 Whatever the levels of
genetic diversity, devils are able to reject skin grafts
within 14–21 days even when the donor and recipient
have identical MHC class I and/or class II genotypes or
MHC genes with only one or two non-synonymous
mutations,83 indicating that MHC diversity cannot
explain the ability of DFTD to pass between individ-
uals.
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Discussion
MHC expression or low genetic diversity, which to
blame for the emergence of a contagious cancer?
Two primary hypotheses have been put forward to
explain the emergence of DFTD and CTVT: first that low
levels of genetic diversity are necessary for these transmis-
sible tumours to emerge and second that immune evasion
strategies, including loss of MHC molecules, are neces-
sary. So which is to blame? Both CTVT and DFTD
down-regulate MHC molecules and many single organism
tumours also acquire mutations leading to the loss of
MHC, which is often associated with a poor prognosis
and metastasis (reviewed in ref. 73). However, while sin-
gle organism tumours may or may not have altered self
antigens that distinguish them from healthy cells, DFTD
and CTVT as allografts certainly should, and this most
likely placed a greater selective pressure on the tumour
cells to down-regulate MHC molecules and may have
been necessary for the initial transmission events. How-
ever, solid tumours are often not simply MHC positive
or MHC negative, rather they are made up of a heteroge-
neous population of cells. This seems to also be true of
DFTD and CTVT, which can exist in both MHC-positive
and MHC-negative states.
Both DFTD and CTVT appear to regulate MHC expres-
sion by epigenetic mechanisms.35,75 In single organism
tumours, loss of MHC molecules can occur via epigenetic
regulation, but loss is more common by structural muta-
tions in DNA,84 presumably as these mutations prevent
MHC expression being rescued by changes in the microen-
vironment, including cytokine release. In contrast, both
CTVT and DFTD have retained the ability to express MHC
in certain contexts and for CTVT this may have been an
evolutionary advantage; eventual MHC expression allows
the dog immune system to control tumour growth, pre-
venting death of the host and allowing sufficient time for
the tumour to be transmitted.35 Although the epigenetic
mechanisms responsible for MHC loss in DFTD are not yet
understood, they may be indicative of global changes of
chromatin remodelling and/or methylation patterns that
occurred in these cells when they transformed to malig-
nancy.
The ability of CTVT and DFTD to up-regulate MHC
molecules in response to IFN-c means that the MHC
genotype may still impact tumour growth despite the loss
of MHC molecules for transmission and growth. As the
extent of MHC compatibility affects the speed of graft
rejection, one scenario is that low genetic diversity leads
to slower anti-graft responses during the transmission of
a tumour, facilitating early transmission events. There is
some evidence that the speed of CTVT regression is gov-
erned by the MHC genotype of the host dog,26 but in the
case of DFTD this area remains largely unexplored.
Although MHC genotype does not correlate with DFTD
susceptibility, the effect of MHC genotype on tumour
growth rate has not been investigated.78 Further investiga-
tion is needed to tease out the role of immune evasion
and genetic diversity on the immune response to DFTD.
The impact of CTVT and DFTD on their host
In contrast to CTVT, DFTD maintains its escape pheno-
type despite its susceptibility to IFN-c. In some human
and mouse tumour models MHC restricted recognition
of tumour antigens by CD8+ T cells can be insufficient to
trigger an anti-tumour response because of other immu-
nosuppressive factors.85 It may be significant that a quar-
ter of DFTD tumours were found to have lymphocytes at
the periphery of the tumour mass and our own observa-
tions indicate that CD3-positive cells can gather at the
edges of tumours without obvious infiltration.40,75 Lack
of infiltration may indicate that the microenvironment is
promoting tumour growth and immunosuppression (as
in ref. 86), or these CD3 cells may be tolerogenic (i.e. T
regulatory cells) (as in ref. 87).
The current understanding of immune escape by DFTD
and CTVT cells does not explain sufficiently the ability of
these tumours to cross histocompatibility barriers so read-
ily. For example, these tumour cells should be susceptible
to lysis by NK cells, which will target cells without an
appropriate inhibitory ligand, such as MHC class I. One
would imagine that this would be of particular impor-
tance when DFTD and CTVT cells are transmitted, before
the formation of a solid tumour. It is possible that DFTD
and CTVT cells express alternative inhibitory ligands to
classical MHC class I and/or down-regulate activating
ligands to avoid NK cell lysis during transmission. NK
cells have been identified by functional assays in the Tas-
manian devil,88 but at present nothing is known about
the markers that they express. However, C-type lectin and
immunoglobulin-like genes similar to NK cell receptors
in other species have recently been identified in the
Tasmanian devil genome89 and hopefully this will assist in
identifying both activating and inhibitory receptors on
devil NK cells.
Contagious cancers in humans?
Naturally occurring contagious cancers are rare, but quasi-
contagious cancers have been reported in humans on
numerous occasions. Examples of tumour cell transfer
between humans has been reviewed elsewhere,90 but the
primary methods of transfer are from mother to foetus
during pregnancy and during transplant procedures, with
rare instances occurring during surgery. The types of cancer
cells passed are predominantly melanoma and leukaemia/
lymphoma, presumably due to the metastatic potential of
these tumour types.90 In some cases, transferred tumour
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cells lose expression of non-maternal HLA,91 and in others
the tumour cells engraft areas that have a level of immuno-
logical privilege,92 although in most cases the mechanisms
of immune escape have not been described. In all cases
reported the tumour cells have no means of natural trans-
mission but these instances illustrate that a contagious can-
cer could emerge in humans, and of course single organism
tumours readily become resistant to the immune system
and immunotherapy.
Conclusions and future directions
Only two naturally contagious cancers have been
described, CTVT in dogs and DFTD in Tasmanian devils.
DFTD is an example of a contagious cancer that has had
a devastating effect on the host, reducing the Tasmanian
devil population drastically, whereas CTVT is more
benign, coexisting over a long period of time with its
host. Whether CTVT was once a more aggressive tumour
and had a more significant impact on its host is an open
question. Many other questions remain unanswered in
the development of both DFTD and CTVT. For example,
the dynamics of transmission are poorly understood; in a
natural setting how many DFTD and CTVT cells are
required for tumour growth? Is there an ideal time-point
for transmission of these tumours? Do proliferating cells
(cancer stem cells) need to be transmitted? What is the
interplay of immune evasion and MHC genetics in the
success of these tumours?
With further investigation of the immune escape mech-
anisms of DFTD cells, we hope to unravel how a conta-
gious cancer can emerge, the more general requirements
for transmissibility and fundamental mechanisms of
tumour immune evasion and evolution. Most impor-
tantly, our understanding of how DFTD cells evade the
immune response should reveal how to reverse these
mechanisms and develop a vaccine against DFTD.
Acknowledgements
This work was supported by Wellcome Trust programme
Grant 089305 (to JK) and a University of Tasmania Dr
Eric Guiler Tasmanian Devil Research Grant (to HVS).
The authors would like to thank Menna Jones, Rodrigo
Hamede, Alexandre Kreiss and Gregory Woods for help-
ful comments on the manuscript.
Disclosure
The authors declare no competing interests.
References
1 Ehrlich P. Ueber den jetzigen stand der Karzinomforschung. Ned Tijdschr Geneeskd
1909; 5:273–90.
2 Burnet FM. Cancer – a biological approach. Br Med J 1957; 1:841–7.
3 Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD. IFNc
and lymphocytes prevent primary tumour development and shape tumour immunoge-
nicity. Nature 2001; 410:1107–11.
4 Matsushita H, Vesely MD, Koboldt DC et al. Cancer exome analysis reveals a T-cell-
dependent mechanism of cancer immunoediting. Nature 2012; 482:400–4.
5 Klein E, Klein G, Revesz L. Permanent modification (mutation?) of a histocompatibility
gene in a heterozygous tumor. J Natl Cancer Inst 1957; 19:95–114.
6 Murchison EP, Wedge DC, Alexandrov LB et al. Transmissible [corrected] dog cancer
genome reveals the origin and history of an ancient cell lineage. Science 2014; 343:437–
40.
7 McCallum H, Jones M. To lose both would look like carelessness: Tasmanian devil
facial tumour disease. PLoS Biol 2006; 4:e342.
8 McCallum H, Tompkins DM, Jones ME et al. Distribution and impacts of Tasma-
nian devil facial tumor disease. EcoHealth 2007; 4:318–25.
9 Rosenberg AS. The T cell populations mediating rejection of MHC class I disparate skin
grafts in mice. Transpl Immunol 1993; 1:93–9.
10 Rosenberg AS, Singer A. Cellular basis of skin allograft rejection: an in vivo model of
immune-mediated tissue destruction. Annu Rev Immunol 1992; 10:333–58.
11 Benichou G, Takizawa PA, Olson CA, McMillan M, Sercarz EE. Donor major histo-
compatibility complex (MHC) peptides are presented by recipient MHC molecules dur-
ing graft rejection. J Exp Med 1992; 175:305–8.
12 Taner T, Gandhi MJ, Sanderson SO, Poterucha CR, De Goey SR, Stegall MD,
Heimbach JK. Prevalence, course and impact of HLA donor-specific antibodies in liver
transplantation in the first year. Am J Transplant 2012; 12:1504–10.
13 Diefenbach A, Hsia JK, Hsiung MY, Raulet DH. A novel ligand for the NKG2D recep-
tor activates NK cells and macrophages and induces tumor immunity. Eur J Immunol
2003; 33:381–91.
14 Fridman WH, Mlecnik B, Bindea G, Pages F, Galon J. Immunosurveillance in human
non-viral cancers. Curr Opin Immunol 2011; 23:272–8.
15 Cerwenka A, Lanier LL. Natural killer cells, viruses and cancer. Nat Rev Immunol 2001;
1:41–9.
16 Quezada SA, Peggs KS, Simpson TR, Allison JP. Shifting the equilibrium in cancer
immunoediting: from tumor tolerance to eradication. Immunol Rev 2011; 241:104–
18.
17 Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance
and immunoediting. Immunity 2004; 21:137–48.
18 Novinsky MA. Zur Frage uber die Impfung der Krebsigen Geschwulste. Zentralbl Med
Wissensch 1876; 14:53–84.
19 Levy E, Mylonakis ME, Saridomichelakis MN, Polizopoulou ZS, Psychogios V, Koutinas
AF. Nasal and oral masses in a dog. Vet Clin Pathol 2006; 35:115–8.
20 Milo J, Snead E. A case of ocular canine transmissible venereal tumor. Can Vet J 2014;
55:1245–9.
21 Cohen D, Steel GG. Thymidine labelling studies in a transmissible venereal tumour of
the dog. Br J Cancer 1972; 26:413–9.
22 Karlson AG, Mann FC. The transmissible venereal tumor of dogs: observations on forty
generations of experimental transfers. Ann N Y Acad Sci 1952; 54:1197–213.
23 Cohen D. The canine transmissible venereal tumor: a unique result of tumor progres-
sion. Adv Cancer Res 1985; 43:75–112.
24 Cohen D. The biological behaviour of the transmissible venereal tumour in immuno-
suppressed dogs. Eur J Cancer 1973; 9:253–8.
25 Yang TJ, Jones JB. Canine transmissible venereal sarcoma: transplantation studies in
neonatal and adult dogs. J Natl Cancer Inst 1973; 51:1915–8.
26 Epstein RB, Bennett BT. Histocompatibility typing and course of canine venereal
tumors transplanted into unmodified random dogs. Cancer Res 1974; 34:788–93.
27 Holmes JM. Measurement of the rate of death of dog tumour cells transplanted into a-
thymic “nude” mice. J Comp Pathol 1981; 91:511–9.
28 Yang TJ. Regression of canine transmissible venereal sarcoma. J Am Vet Med Assoc
1987; 191:6.
29 Brown NO, Calvert C, MacEwen EG. Chemotherapeutic management of transmissible
venereal tumors in 30 dogs. J Am Vet Med Assoc 1980; 176(10 Pt 1):983–6.
30 Higgins DA. Observations on the canine transmissible venereal tumour as seen in the
Bahamas. Vet Res 1996; 79:67–71.
31 Mozos E, Mendez A, Gomez-Villamandos JC, Martin De Las Mulas J, Perez J. Immu-
nohistochemical characterization of canine transmissible venereal tumor. Vet Pathol
1996; 33:257–63.
32 Marchal T, Chabanne L, Kaplanski C, Rigal D, Magnol JP. Immunophenotype of
the canine transmissible venereal tumour. Vet Immunol Immunopathol 1997; 57:
1–11.
33 Catone G, Marino G, Poglayen G, Gramiccia M, Ludovisi A, Zanghi A. Canine trans-
missible venereal tumour parasitized by Leishmania infantum. Vet Res Commun 2003;
27:549–53.
ª 2014 The Authors. Immunology published by John Wiley & Sons Ltd., Immunology, 144, 11–2018
H. V. Siddle and J. Kaufman
34 Chiang HC, Liao AT, Jan TR et al. Gene-expression profiling to identify genes related
to spontaneous tumor regression in a canine cancer model. Vet Immunol Immunopathol
2013; 151:207–16.
35 Murgia C, Pritchard JK, Kim SY, Fassati A, Weiss RA. Clonal origin and evolution of a
transmissible cancer. Cell 2006; 126:477–87.
36 Rebbeck CA, Thomas R, Breen M, Leroi AM, Burt A. Origins and evolution of a trans-
missible cancer. Evolution 2009; 63:2340–9.
37 Hawkins C, Baars C, Hesterman H et al. Emerging disease and population decline of
an island endemic, the Tasmanian devil Sarcophilus harrisii. Biol Conserv 2006;
131:307–24.
38 Loh R, Bergfeld J, Hayes D, O’Hara A, Pyecroft S, Raidal S, Sharpe R. The pathology of
devil facial tumor disease (DFTD) in Tasmanian Devils (Sarcophilus harrisii). Vet Pathol
2006; 43:890–5.
39 Hamede RK, McCallum H, Jones M. Biting injuries and transmission of Tasmanian
devil facial tumour disease. J Anim Ecol 2013; 82:182–90.
40 Loh R, Hayes D, Mahjoor A, O’Hara A, Pyecroft S, Raidal S. The immunohistochemical
characterization of devil facial tumor disease (DFTD) in the Tasmanian Devil (Sarcophi-
lus harrisii). Vet Pathol 2006; 43:896–903.
41 Murchison EP, Tovar C, Hsu A et al. The Tasmanian devil transcriptome reveals
Schwann cell origins of a clonally transmissible cancer. Science 2010; 327:
84–7.
42 Tovar C, Obendorf D, Murchison EP, Papenfuss AT, Kreiss A, Woods GM. Tumor-spe-
cific diagnostic marker for transmissible facial tumors of Tasmanian devils: immunohis-
tochemistry studies. Vet Pathol 2011; 48:1195–203.
43 Pearse AM, Swift K. Allograft theory: transmission of devil facial-tumour disease. Nat-
ure 2006; 439:549.
44 Siddle HV, Kreiss A, Eldridge MD, Noonan E, Clarke CJ, Pyecroft S et al. Transmission
of a fatal clonal tumor by biting occurs due to depleted MHC diversity in a threatened
carnivorous marsupial. Proc Natl Acad Sci USA 2007; 104:16221–6.
45 Deakin JE, Bender HS, Pearse AM et al. Genomic restructuring in the Tasmanian devil
facial tumour: chromosome painting and gene mapping provide clues to evolution of a
transmissible tumour. PLoS Genet 2012; 8:e1002483.
46 Murchison EP, Schulz-Trieglaff OB, Ning Z et al. Genome sequencing and analysis of
the Tasmanian devil and its transmissible cancer. Cell 2012; 148:780–91.
47 Pearse AM, Swift K, Hodson P et al. Evolution in a transmissible cancer: a study of the
chromosomal changes in devil facial tumor (DFT) as it spreads through the wild Tas-
manian devil population. Cancer Genet 2012; 205:101–12.
48 Jones M, Oakwood M, Belcher C et al. Carnivore Concerns: Problems, Issues, and Solu-
tions for Conserving Australia’s Marsupial Carnivores. Jones M, Dickman C, Archer M,
eds. Melbourne, Vic, Australia: CSIRO Publishing, 2003:422–34.
49 Hamede RK, McCallum H, Jones M. Seasonal, demographic and density-related pat-
terns of contact between Tasmanian devils (Sarcophilus harrisii): implications for trans-
mission of devil facial tumour disease. Austral Ecol 2008; 33:614–22.
50 Hamede RK, Bashford J, McCallum H, Jones M. Contact networks in a wild Tasmanian
devil (Sarcophilus harrisii) population: using social network analysis to reveal seasonal
variability in social behaviour and its implications for transmission of devil facial
tumour disease. Ecol Lett 2009; 12:1147–57.
51 McCallum H, Jones M, Hawkins C, Hamede R, Lachish S, Sinn DL, Beeton N, Lazenby
B. Transmission dynamics of Tasmanian devil facial tumor disease may lead to disease-
induced extinction. Ecology 2009; 90:3379–92.
52 Lachish S, McCallum H, Jones M. Demography, disease and the devil: life-history
changes in a disease-affected population of Tasmanian devils (Sarcophilus harrisii).
J Anim Ecol 2009; 78:427–36.
53 Lachish S, Miller KJ, Storfer A, Goldizen AW, Jones ME. Evidence that disease-induced
population decline changes genetic structure and alters dispersal patterns in the Tasma-
nian devil. Heredity 2014; 106:172–82.
54 Hamede R, Lachish S, Belov K et al. Reduced effect of Tasmanian devil facial tumor
disease at the disease front. Conserv Biol 2012; 26:124–34.
55 Cohen D. Detection of humoral antibody to the transmissible venereal tumour of the
dog. Int J Cancer 1972; 10:207–12.
56 Perez J, Day MJ, Mozos E. Immunohistochemical study of the local inflammatory infil-
trate in spontaneous canine transmissible venereal tumour at different stages of growth.
Vet Immunol Immunopathol 1998; 64:133–47.
57 Chandler JP, Yang TJ. Canine transmissible venereal sarcoma: distribution of T and B
lymphocytes in blood, draining lymph nodes and tumours at different stages of growth.
Br J Cancer 1981; 44:514–21.
58 Trail PA, Yang TJ. Canine transmissible venereal sarcoma: quantitation of T-lympho-
cyte subpopulations during progressive growth and spontaneous tumor regression.
J Natl Cancer Inst 1985; 74:461–7.
59 Hsiao YW, Liao KW, Hung SW, Chu RM. Tumor-infiltrating lymphocyte secretion of
IL-6 antagonizes tumor-derived TGF-b1 and restores the lymphokine-activated killing
activity. J Immunol 2004; 172:1508–14.
60 Hsiao YW, Liao KW, Hung SW, Chu RM. Effect of tumor infiltrating lymphocytes on
the expression of MHC molecules in canine transmissible venereal tumor cells. Vet
Immunol Immunopathol 2002; 87:19–27.
61 Yang TJ, Chandler JP, Dunne-Anway S. Growth stage dependent expression of
MHC antigens on the canine transmissible venereal sarcoma. Br J Cancer 1987; 55:
131–4.
62 Hsiao YW, Liao KW, Chung TF, Liu CH, Hsu CD, Chu RM. Interactions of host IL-6
and IFN-c and cancer-derived TGF-b1 on MHC molecule expression during tumor
spontaneous regression. Cancer Immunol Immunother 2008; 57:1091–104.
63 Mizuno S, Fujinaga T, Tajima M, Otomo K, Koike T. Role of lymphocytes in dogs
experimentally re-challenged with canine transmissible sarcoma. Nihon Juigaku Zasshi
1989; 51:86–95.
64 Powers RD. Immunologic properties of canine transmissible venereal sarcoma. Am J
Vet Res 1968; 29:1637–45.
65 Cohen D. In vitro cell-mediated cytotoxicity and antibody-dependent cellular cytotoxic-
ity to the transmissible venereal tumor of the dog. J Natl Cancer Inst 1980; 64:317–21.
66 Palker TJ, Yang TJ. Identification and physicochemical characterization of a tumor-
associated antigen from canine transmissible venereal sarcoma. J Natl Cancer Inst 1981;
66:779–87.
67 Phalen DN, Frimberger A, Pyecroft S et al. Vincristine chemotherapy trials and phar-
macokinetics in Tasmanian devils with Tasmanian devil facial tumor disease. PLoS
ONE 2013; 8:e65133.
68 Howson LJ, Morris KM, Kobayashi T et al. Identification of dendritic cells, B cell and
T cell subsets in Tasmanian devil lymphoid tissue; evidence for poor immune cell infil-
tration into devil facial tumors. Anat Rec (Hoboken) 2014; 297:925–38.
69 Kreiss A, Obendorf DL, Hemsley S, Canfield PJ, Woods GM. A histological and immu-
nohistochemical analysis of lymphoid tissues of the Tasmanian devil. Anat Rec (Hobo-
ken) 2009; 292:611–20.
70 Kreiss A, Fox N, Bergfeld J, Quinn SJ, Pyecroft S, Woods GM. Assessment of cellular
immune responses of healthy and diseased Tasmanian devils (Sarcophilus harrisii). Dev
Comp Immunol 2008; 32:544–53.
71 Kreiss A, Tovar C, Obendorf DL, Dun K, Woods GM. A murine xenograft model for a
transmissible cancer in Tasmanian devils. Vet Pathol 2011; 48:475–81.
72 Restifo NP, Marincola FM, Kawakami Y, Taubenberger J, Yannelli JR, Rosenberg SA.
Loss of functional b2-microglobulin in metastatic melanomas from five patients receiv-
ing immunotherapy. J Natl Cancer Inst 1996; 88:100–8.
73 Chang CC, Campoli M, Ferrone S. Classical and nonclassical HLA class I antigen and
NK cell-activating ligand changes in malignant cells: current challenges and future
directions. Adv Cancer Res 2005; 93:189–234.
74 Cohen D, Shalev A, Krup M. Lack of b2-microglobulin on the surface of canine trans-
missible venereal tumor cells. J Natl Cancer Inst 1984; 72:395–401.
75 Siddle HV, Kreiss A, Tovar C et al. Reversible epigenetic down-regulation of MHC
molecules by devil facial tumour disease illustrates immune escape by a contagious can-
cer. Proc Natl Acad Sci USA 2013; 110:5103–8.
76 Morris K, Belov K. Does the devil facial tumour produce immunosuppressive cytokines
as an immune evasion strategy? Vet Immunol Immunopathol 2013; 153:159–64.
77 Jimenez P, Canton J, Collado A et al. Chromosome loss is the most frequent mecha-
nism contributing to HLA haplotype loss in human tumors. Int J Cancer 1999; 83:91–7.
78 Lane A, Cheng Y, Wright B, Hamede R, Levan L, Jones M, Ujvari B, Belov K. New
insights into the role of MHC diversity in devil facial tumour disease. PLoS ONE 2012;
7:e36955.
79 Cheng Y, Stuart A, Morris K et al. Antigen-presenting genes and genomic copy number
variations in the Tasmanian devil MHC. BMC Genomics 2012; 13:87.
80 Siddle HV, Marzec J, Cheng Y, Jones M, Belov K. MHC gene copy number variation in
Tasmanian devils: implications for the spread of a contagious cancer. Proc Biol Sci
2010; 277:2001–6.
81 Jones ME, Paetkau D, Geffen E, Moritz C. Genetic diversity and population struc-
ture of Tasmanian devils, the largest marsupial carnivore. Mol Ecol 2004; 13:2197–
209.
82 Miller W, Hayes VM, Ratan A et al. Genetic diversity and population structure of the
endangered marsupial Sarcophilus harrisii (Tasmanian devil). Proc Natl Acad Sci USA
2011; 108:12348–53.
83 Kreiss A, Cheng Y, Kimble F, Wells B, Donovan S, Belov K, Woods GM. Allorecogni-
tion in the Tasmanian devil (Sarcophilus harrisii), an endangered marsupial species with
limited genetic diversity. PLoS ONE 2011; 6:e22402.
84 Manning J, Indrova M, Lubyova B et al. Induction of MHC class I molecule cell surface
expression and epigenetic activation of antigen-processing machinery components in a
murine model for human papilloma virus 16-associated tumours. Immunology 2008;
123:218–27.
85 Rosenberg SA, Sherry RM, Morton KE et al. Tumor progression can occur despite the
induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients
with melanoma. J Immunol 2005; 175:6169–76.
ª 2014 The Authors. Immunology published by John Wiley & Sons Ltd., Immunology, 144, 11–20 19
Immunology of naturally transmissible tumours
86 Feig C, Jones JO, Kraman M et al. Targeting CXCL12 from FAP-expressing carcinoma-
associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer.
Proc Natl Acad Sci USA 2013; 110:20212–7.
87 Curiel TJ, Coukos G, Zou L et al. Specific recruitment of regulatory T cells in ovarian
carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;
10:942–9.
88 Brown GK, Kreiss A, Lyons AB, Woods GM. Natural killer cell mediated cytotoxic
responses in the Tasmanian devil. PLoS ONE 2011; 6:e24475.
89 van der Kraan LE, Wong ES, Lo N, Ujvari B, Belov K. Identification of natural killer
cell receptor genes in the genome of the marsupial Tasmanian devil (Sarcophilus harris-
ii). Immunogenetics 2013; 65:25–35.
90 Focosi D, De Donno M, Barbuti S, Davini S, Fornaciari S, Curcio M, Mariotti ML,
Scatena F. Cancer transmissibility across HLA barriers between immunocompetent indi-
viduals: rare but not impossible. Hum Immunol 2011; 72:1–4.
91 Isoda T, Ford AM, Tomizawa D et al. Immunologically silent cancer clone transmission
from mother to offspring. Proc Natl Acad Sci USA 2009; 106:17882–5.
92 Yagasaki H, Ohashi H, Ito M, Kobayashi S, Kato M, Shichino H, Chin M,
Mugishima H. A novel mechanism of transplacental cancer transmission: natural
killer/T-cell lymphoma in the paratesticular region is of maternal origin. Blood 2011;
117:6046–7.
ª 2014 The Authors. Immunology published by John Wiley & Sons Ltd., Immunology, 144, 11–2020
H. V. Siddle and J. Kaufman
